Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$78.46

-0.81 (-1.02%)

11:17
10/17/16
10/17
11:17
10/17/16
11:17

Eli Lilly announces partnership with National Cancer Insititute

Eli Lilly and Company announced it will contribute cancer research data to the National Cancer Institute's Blood Profiling Atlas, an open access liquid biopsy database being created in response to Vice President Joe Biden's call to action and in alignment with the goals of the Cancer Moonshot initiative. The database is an effort to reduce the development time of effective and safe blood profiling diagnostic technologies. In support of this overarching mission, Lilly is studying approaches for the profiling of exosomes for mRNA and non-coding RNA expression and will share sample preparation methods, next-generation quantitative PCR-based methods, and next generation sequencing-based methods along with data related to disease characterization through gene expression analysis.

  • 25

    Oct

  • 06

    Nov

LLY Eli Lilly
$78.46

-0.81 (-1.02%)

09/27/16
GSCO
09/27/16
UPGRADE
Target $95
GSCO
Buy
Eli Lilly upgraded to Buy from Neutral at Goldman
Goldman analyst Jami Rubin upgraded Eli Lilly to Buy and increased its price target to $95 from $89 saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. Rubin projects $12.5B of new product sales by 2020 and double digit earnings growth over the next five years, even without Sola. The analyst sees a 35%, up from 25%, probability of success for Sola with a bull case scenario that can lead to almost $7.5B in peak sales and "super charge" earnings. Even without Sola, Rubin sees favorable risk/reward given durability of earnings and said it is the least exposed to above-CPI price increases.
09/27/16
09/27/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Neutral at Goldman with analyst Jami Rubin saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. 2. AutoZone (AZO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying the company is at a positive inflection in 7 year and older vehicles, which is strongly correlated to same-store-sales. 3. Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI with analyst Greg Gordon saying the joint settlement proposal filed in the CECONY rate case mitigates downside risk. 4. Crown Holdings (CCK) upgraded on multiple catalysts at BMO Capital with analyst Mark Wilde citing valuation, his belief that the company will resume returning cash to shareholders in 2017, and his belief that the company's results should be boosted by " a wave of domestic and offshore expansion projects." 5. Francesca's (FRAN) upgraded to Buy from Hold at Stifel with analyst Richard Jaffe saying the company's "appealing merchandise" makes it very likely that its sales will grow going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.

TODAY'S FREE FLY STORIES

BCRX

BioCryst

$5.49

-0.11 (-1.96%)

06:08
02/27/17
02/27
06:08
02/27/17
06:08
Hot Stocks
BioCryst reports 'positive' interim results from APeX-1 trial »

BioCryst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

06:08
02/27/17
02/27
06:08
02/27/17
06:08
Downgrade
J.C. Penney rating change  »

J.C. Penney downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

06:07
02/27/17
02/27
06:07
02/27/17
06:07
Hot Stocks
Buffett says market 'not in bubble territory' or 'anything of the sort' »

Warren Buffett, while…

WMT

Wal-Mart

$72.39

1.08 (1.51%)

, KR

Kroger

$33.29

0.3 (0.91%)

06:06
02/27/17
02/27
06:06
02/27/17
06:06
Periodicals
Wal-Mart launching price-comparison test in U.S., targeting Aldi, Reuters says »

Wal-Mart (WMT) is…

WMT

Wal-Mart

$72.39

1.08 (1.51%)

KR

Kroger

$33.29

0.3 (0.91%)

PG

Procter & Gamble

$91.05

-0.08 (-0.09%)

UN

Unilever; also tag UL

$46.91

0.33 (0.71%)

UL

Unilever; also tag UN

$47.12

0.22 (0.47%)

CAG

Conagra Brands

$41.16

0.66 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

LJPC

La Jolla

$19.87

1.65 (9.06%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Hot Stocks
La Jolla announces positive results from ATHOS-3 Phase 3 study of LJPC-501 »

La Jolla Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

INVH

Invitation Homes

$21.60

0.02 (0.09%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEG

PSEG

$45.61

1.36 (3.07%)

06:04
02/27/17
02/27
06:04
02/27/17
06:04
Downgrade
PSEG rating change  »

PSEG downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Hot Stocks
Breaking Hot Stocks news story on UCP, Inc. »

UCP, Inc. reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LAUR

Laureate Education

$13.24

0.06 (0.46%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Initiation
Laureate Education initiated  »

Laureate Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:02
02/27/17
02/27
06:02
02/27/17
06:02
Earnings
UCP, Inc. reports Q4 EPS 89c with benefits, consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SNAP

Snap Inc.

06:01
02/27/17
02/27
06:01
02/27/17
06:01
Periodicals
Snap founders tightened grip following dispute with Lightspeed, NYT reports »

Early Snap investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

GRAM

Grana y Montero

$3.32

-1.77 (-34.77%)

06:00
02/27/17
02/27
06:00
02/27/17
06:00
Downgrade
Grana y Montero rating change  »

Grana y Montero…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$21.60

0.02 (0.09%)

05:59
02/27/17
02/27
05:59
02/27/17
05:59
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.66

0.13 (0.10%)

, EBAY

eBay

$34.06

0.46 (1.37%)

05:58
02/27/17
02/27
05:58
02/27/17
05:58
Periodicals
Tech firms plan to file brief in favor of transgender rights, Axios reports »

Leading tech companies…

AAPL

Apple

$136.66

0.13 (0.10%)

EBAY

eBay

$34.06

0.46 (1.37%)

IBM

IBM

$181.35

-0.3 (-0.17%)

MSFT

Microsoft

PYPL

PayPal

$43.07

0.54 (1.27%)

CRM

Salesforce

$81.78

-0.29 (-0.35%)

YELP

Yelp

$33.46

-0.01 (-0.03%)

BOX

Box

$17.93

0.41 (2.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 06

    Mar

  • 13

    Mar

  • 14

    Mar

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 22

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 09

    May

AFL

Aflac

$71.71

-0.01 (-0.01%)

05:57
02/27/17
02/27
05:57
02/27/17
05:57
Upgrade
Aflac rating change  »

Aflac upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

FTI

TechnipFMC

$32.30

-0.58 (-1.76%)

05:56
02/27/17
02/27
05:56
02/27/17
05:56
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$57.00

2.32 (4.24%)

, ISIL

Intersil

05:55
02/27/17
02/27
05:55
02/27/17
05:55
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$57.00

2.32 (4.24%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$131.21

9.26 (7.59%)

, SE

Spectra Energy

$40.68

-0.32 (-0.78%)

05:55
02/27/17
02/27
05:55
02/27/17
05:55
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$131.21

9.26 (7.59%)

SE

Spectra Energy

$40.68

-0.32 (-0.78%)

ENB

Enbridge

$41.34

-0.37 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

NCMI

National CineMedia

$12.08

-0.35 (-2.82%)

05:53
02/27/17
02/27
05:53
02/27/17
05:53
Recommendations
National CineMedia analyst commentary  »

National CineMedia added…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

HMSY

HMS Holdings

$18.83

0.13 (0.70%)

05:48
02/27/17
02/27
05:48
02/27/17
05:48
Downgrade
HMS Holdings rating change  »

HMS Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

TEX

Terex

$30.35

0.44 (1.47%)

05:45
02/27/17
02/27
05:45
02/27/17
05:45
Upgrade
Terex rating change  »

Terex upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 07

    Mar

TPH

TRI Pointe

$12.21

0.1 (0.83%)

05:43
02/27/17
02/27
05:43
02/27/17
05:43
Downgrade
TRI Pointe rating change  »

TRI Pointe downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

05:39
02/27/17
02/27
05:39
02/27/17
05:39
Recommendations
J.C. Penney analyst commentary  »

J.C. Penney price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

SUI

Sun Communities

$83.52

1.2 (1.46%)

05:37
02/27/17
02/27
05:37
02/27/17
05:37
Downgrade
Sun Communities rating change  »

Sun Communities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

AVGO

Broadcom

$210.37

-0.21 (-0.10%)

05:34
02/27/17
02/27
05:34
02/27/17
05:34
Recommendations
Broadcom analyst commentary  »

Broadcom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 16

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.